Abstract
Preclinical and clinical findings indicate multiple tumour micro-environmental factors, including growth factors, cytokines, cell-cell and cell-matrix adhesion molecules and hypoxia, protect solid tumours from therapeutic interventions. Experimental evidence have defined some of the resistance mechanisms, which have led to the development of innovative approaches aiming at specific targets. While some of these newer approaches have yielded therapeutic benefits in selected tumour types, considerable challenges remain in the management of the majority of patients with solid tumours. This chapter reviews the various tumour microenvironmental factors that contribute to drug resistance. These factors exert their effects through direct promoting resistance effectors and/or indirectly modulating other environmental factors. Furthermore, cooperative regulation, cross-talk and redundancy at different levels of signaling cascades affect the tumour progression and drug resistance, and can diminish the effectiveness of the single target therapeutic approach. A better understanding of the intersecting resistance pathways has the potential of leading to new therapeutic paradigms aiming at multiple targets, in order to overcome the microenvironment-conferred survival advantage to tumour cells.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Farber, S., Diamond, L.K., Mercer, R.D., Sylvester, R.F., and Wolff, R.D., 1948, Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J, 238:787–793.
Nygren, P., 2001, What is cancer chemotherapy? Acta Oncol, 40:166–174.
Borges-Walmsley, M. I., McKeegan, K. S., and Walmsley, A. R., 2003, Structure and function of efflux pumps that confer resistance to drugs. Biochem J, 376:313–338.
Leonessa, F., and Clarke, R., 2003, ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer, 10:43–73.
Varadi, A., Szakacs, G., Bakos, E., and Sarkadi, B., 2002, P glycoprotein and the mechanism of multidrug resistance. Novartis Found Symp, 243:54–65.
Gottesman, M.M., Fojo, T., and Bates, S.E., 2002, Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer, 2:48–58.
Litman, T., Druley, T.E., Stein, W. D., and Bates, S.E., 2001, From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci, 58:931–959.
Persidis, A., 1999, Cancer multidrug resistance. Nat Biotechnol, 17:94–95.
Townsend, D.M., and Tew, K.D., 2003, The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene, 22:7369–7375.
Hayes, J.D., and Pulford, D.J., 1995, The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol, 30:445–600.
Rasheed, Z.A., and Rubin, E.H., 2003, Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene, 22:7296–7304.
Dingemans, A.M., Pinedo, H.M., and Giaccone, G., 1998, Clinical resistance to topoisomerase-targeted drugs. Biochim Biophys Acta, 1400:275–288.
Orr, G. A., Verdier-Pinard, P., McDaid, H., and Horwitz, S.B., 2003, Mechanisms of Taxol resistance related to microtubules. Oncogene, 22:7280–7295.
Drukman, S., and Kavallaris, M., 2002, Microtubule alterations and resistance to tubulin-binding agents (review). Int J Oncol, 21:621–628.
Sangrajrang, S., and Fellous, A., 2000, Taxol resistance. Chemotherapy, 46:327–334.
Hersey, P., and Zhang, X. D., 2003, Overcoming resistance of cancer cells to apoptosis. J Cell Physiol, 196:9–18.
Tolomeo, M., and Simoni, D., 2002, Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies. Curr Med Chem Anti-Canc Agents, 2:387–401.
Reed, J.C., 1995, Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am, 9:451–473.
Nygren, P., and Larsson, R., 2003, Overview of the clinical efficacy of investigational anticancer drugs. J Intern Med, 253:46–75.
Teicher, B.A., Herman, T.S., Holden, S.A., Wang, Y.Y., Pfeffer, M.R., Crawford, J.W., and Frei, III, E., 1990, Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science, 247:1457–1461.
Hoffman, R.M., 1999, Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs, 17:343–359.
Kuo, T.H., Kubota, T., Watanabe, M., Furukawa, T., Kase, S., Tanino, H., Saikawa, Y., Ishibiki, K., Kitajima, M., and Hoffman, R. M., 1993, Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data. Anticancer Res, 13:627–630.
Wilmanns, C., Fan, D., O'Brian, C.A., Bucana, C.D., and Fidler, I.J., 1992, Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer, 52:98–104.
Fidler, I.J., Wilmanns, C., Staroselsky, A., Radinsky, R., Dong, Z., and Fan, D., 1994, Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev, 13:209–222.
Ahn, K.S., Jung, Y.S., Kim, J., Lee, H., and Yoon, S.S., 2001, Behavior of murine renal carcinoma cells grown in ectopic or orthotopic sites in syngeneic mice. Tumour Biol, 22:146–153.
Song, S., Wientjes, M.G., Gan, Y., and Au, J.L., 2000, Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA, 97:8658–8663.
Paull, K.D., Shoemaker, R.H., Hodes, L., Monks, A., Scudiero, D.A., Rubinstein, L., Plowman, J., and Boyd, M.R., 1989, Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst, 81:1088–1092.
Laskin, J.J., and Sandler, A.B., 2004, Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev, 30:1–17.
Ciardiello, F. and Tortora, G., 2003, Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer, 39:1348–1354.
Holbro, T., Civenni, G., and Hynes, N.E., 2003, The ErbB receptors and their role in cancer progression. Exp Cell Res, 284:99–110
Lichtner, R.B., 2003, Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies. Biomed Pharmacother, 57:447–451.
Nicholson, R.I., Gee, J.M., and Harper, M.E., 2001, EGFR and cancer prognosis. Eur J Cancer, 37Suppl 4:S9–15.
Lorenzo, G.D., Bianco, R., Tortora, G., and Ciardiello, F., 2003, Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clin Prostate Cancer, 2:50–57.
Sartor, C.I., 2003, Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin.Radiat.Oncol., 13: 22–30.
Ang, K.K., Andratschke, N.H., and Milas, L., 2004, Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys, 58:959–965.
Meden, H., Marx, D., Roegglen, T., Schauer, A., and Kuhn, W., 1998, Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol, 17:61–65.
Felip, E., Del Campo, J.M., Rubio, D., Vidal, M.T., Colomer, R., and Bermejo, B., 1995, Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer, 75:2147–2152.
Niibe, Y., Nakano, T., Ohno, T., Suzuki, Y., Oka, K., and Tsujii, H., 2003, Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. Int J Gynecol Cancer, 13: 849–855.
Chakravarti, A., Dicker, A., and Mehta, M., 2004, The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys, 58:927–931.
Kari, C., Chan, T. O., Rocha, d. Q., and Rodeck, U. 2003, Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res, 63:1–5.
Kumar, R., Mandal, M., Lipton, A., Harvey, H., and Thompson, C.B., 1996, Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res, 2:1215–1219.
Golubovskaya, V., Beviglia, L., Xu, L. H., Earp, III, H. S., Craven, R., and Cance, W., 2002, Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem, 277:38978–38987.
Cao, L., Yao, Y., Lee, V., Kiani, C., Spaner, D., Lin, Z., Zhang, Y., Adams, M.E., and Yang, B.B., 2000, Epidermal growth factor induces cell cycle arrest and apoptosis of squamous carcinoma cells through reduction of cell adhesion. J Cell Biochem, 77:569–583.
Kottke, T.J., Blajeski, A.L., Martins, L.M., Mesner, Jr., P.W., Davidson, N.E., Earnshaw, W.C., Armstrong, D.K., and Kaufmann, S.H., 1999, Comparison of paclitaxel-, 5-fluoro-2′-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis. J Biol Chem, 274:15927–15936.
Allen, G. C., Lubas, S., Wax, M. K., and Devore, R. F., III 1996. Epidermal growth factor regulates topoisomerase II activity and drug sensitivity in human KB cells. Otolaryngol.Head Neck Surg., 114:785–792.
Boudny, V., Murakami, Y., Nakano, S., and Niho, Y., 1999, Expression of activated c-erbB-2 oncogene induces sensitivity to cisplatin in human gallbladder adenocarcinoma cells. Anticancer Res, 19:5203–5206.
Kroning, R., Jones, J.A., Hom, D.K., Chuang, C. C., Sanga, R., Los, G., Howell, S. B., and Christen, R. D., 1995, Enhancement of drug sensitivity of human malignancies by epidermal growth factor. Br J Cancer, 72:615–619.
Amagase, H., Tamura, K., Hashimoto, K., Fuwa, T., Murakami, T., and Yata, N., 1990, Response of A431 experimental human solid xenograft to mitomycin C in combination with human epidermal growth factor in mice. J Pharmacobiodyn, 13:263–268.
Ling, Y.H., Donato, N.J., and Perez-Soler, R., 2001, Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines. Cancer Chemother Pharmacol, 47:473–480.
Thor, A.D., Berry, D.A., Budman, D.R., Muss, H.B., Kute, T., Henderson, I.C., Barcos, M., Cirrincione, C., Edgerton, S., Allred, C., Norton, L., and Liu, E.T., 1998, erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst, 90:1346–1360.
Campiglio, M., Somenzi, G., Olgiati, C., Beretta, G., Balsari, A., Zaffaroni, N., Valagussa, P., and Menard, S., 2003, Role of proliferation in HER2 status predicted response to doxorubicin. Int J Cancer, 105:568–573.
Paik, S., Bryant, J., Park, C., Fisher, B., Tan-Chiu, E., Hyams, D., Fisher, E.R., Lippman, M.E., Wickerham, D.L., and Wolmark, N., 1998, erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst, 90:1361–1370.
Clark, G.M., 1998, Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?. J Natl Cancer Inst, 90:1320–1321.
Muss, H.B., Thor, A.D., Berry, D.A., Kute, T., Liu, E.T., Koerner, F., Cirrincione, C.T., Budman, D.R., Wood, W.C., and Barcos, M., 1994, c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med, 330:1260–1266.
Gandour-Edwards, R., Lara, Jr., P.N., Folkins, A.K., LaSalle, J.M., Beckett, L., Li, Y., Meyers, F.J., and DeVere-White, R., 2002, Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?. Cancer, 95: 1009–1015.
Baselga, J., Seidman, A.D., Rosen, P.P., and Norton, L., 1997, HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt), 11:43–48.
Koizumi, F., Kanzawa, F., Ueda, Y., Koh, Y., Tsukiyama, S., Taguchi, F., Tamura, T., Saijo, N., and Nishio, K., 2004, Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer, 108:464–472.
Montemurro, F., Valabrega, G., and Aglietta, M., 2004, Trastuzumab-based combination therapy for breast cancer. Expert Opin Pharmacother, 5:81–96.
Ligibel, J.A. and Winer, E.P., 2002, Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol, 29:38–43.
Vogel, C.L., Cobleigh, M.A., Tripathy, D., Gutheil, J.C., Harris, L.N., Fehrenbacher, L., Slamon, D.J., Murphy, M., Novotny, W.F., Burchmore, M., Shak, S., and Stewart, S.J., 2001, First-line Herceptin monotherapy in metastatic breast cancer. Oncology, 61Suppl2: 37–42.
Cobleigh, M.A., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., Fehrenbacher, L., Wolter, J.M., Paton, V., Shak, S., Lieberman, G., and Slamon, D.J., 1999, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17:2639–2648.
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C.C., Dantis, L., Sklarin, N.T., Seidman, A.D., Hudis, C.A., Moore, J., Rosen, P.P., Twaddell, T., Henderson, I.C., and Norton, L., 1996, Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol, 14:737–744.
Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L., 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med, 344:783–792.
Tan, A.R. and Swain, S.M., 2003, Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol, 30:54–64.
Piccart-Gebhart, M.J., 2001, Herceptin: the future in adjuvant breast cancer therapy. Anticancer Drugs, 12Suppl 4:S27–S33.
Slamon, D. and Pegram, M., 2001, Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol, 28:13–19.
Bunn, Jr., P.A., Helfrich, B., Soriano, A.F., Franklin, W.A., Varella-Garcia, M., Hirsch, F. R., Baron, A., Zeng, C., and Chan, D.C., 2001, Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res, 7:3239–3250.
Hirsch, F.R., Helfrich, B., Franklin, W.A., Varella-Garcia, M., Chan, D.C., and Bunn, Jr., P.A., 2002, Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines. Clin Breast Cancer, 3Suppl 1:12–16
Gatzemeier, U., Groth, G., Butts, C., Van Zandwijk, N., Shepherd, F., Ardizzoni, A., Barton, C., Ghahramani, P., and Hirsh, V., 2004, Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol, 15:19–27
Lara, Jr., P.N., Chee, K.G., Longmate, J., Ruel, C., Meyers, F.J., Gray, C.R., Edwards, R.G., Gumerlock, P.H., Twardowski, P., Doroshow, J.H., and Gandara, D.R., 2004, Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer, 100:2125–2131
Ziada, A., Barqawi, A., Glode, L.M., Varella-Garcia, M., Crighton, F., Majeski, S., Rosenblum, M., Kane, M., Chen, L., and Crawford, E.D., 2004, The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate, 60:332–337
Andre, F., Le Chevalier, T., and Soria, J.C., 2004, Her2-neu: a target in lung cancer? Ann Oncol, 15 3–4.
Fernandes, A., Hamburger, A.W., and Gerwin, B.I., 1999, ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int J Cancer, 83:564–570.
Thomas, M., 2003, Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer. Cancer Nurs, 26:21S–25S.
Giaccone, G., 2004, The role of gefitinib in lung cancer treatment. Clin Cancer Res, 10:4233s–4237s.
Perez-Soler, R., 2004, The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res, 10:4238s–4240s.
Xiong, H.Q., Rosenberg, A., LoBuglio, A., Schmidt, W., Wolff, R.A., Deutsch, J., Needle, M., and Abbruzzese, J.L., 2004, Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol, 22:2610–2616.
Saltz, L.B., Meropol, N.J., Loehrer, Sr., P.J., Needle, M.N., Kopit, J., and Mayer, R.J., 2004, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol, 22:1201–1208.
Reynolds, N.A. and Wagstaff, A.J., 2004, Cetuximab: in the treatment of metastatic colorectal cancer. Drugs, 64:109–118.
Herbst, R.S. and Hong, W.K., 2002, IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin Oncol, 29:18–30.
Herbst R.S., Prager D., Hermann R., Miller V., Fehrenbacher L., Hoffman P., Johnson B., Sandler A.B., Mass R., and Johnson D.H., 2004, TRIBUTE-A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). [Abstract]. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 22:#7011.
Gatzemeier U., Pluzanska A., Szczensna A., Kaukel E., Roubec J., Brennscheidt U., De Rosa F., Muller B., and Von Pawel J., 2004, Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). [Abstract]. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 22:#7010.
Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., and Meyerson, M., 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304:1497–1500.
Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., and Haber, D.A., 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Eng J Med, 350:2129–2139.
Sordella, R., Bell, D.W., Haber, D.A., and Settleman, J., 2004, Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science, 305:1163–1167.
Bikfalvi, A., Klein, S., Pintucci, G., and Rifkin, D.B., 1997, Biological roles of fibroblast growth factor-2. Endocr Rev, 18: 26–45.
Ornitz, D.M. and Itoh, N., 2001, Fibroblast growth factors. Genome Biol, 2:REVIEWS3005.
Burgess, W.H. and Maciag, T., 1989, The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem, 58:575–606.
Fuks, Z., Persaud, R.S., Alfieri, A., McLoughlin, M., Ehleiter, D., Schwartz, J.L., Seddon, A.P., Cordon-Cardo, C., and Haimovitz-Friedman, A., 1994, Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res, 54:2582–2590
Yayon, A. and Klagsbrun, M., 1990, Autocrine regulation of cell growth and transformation by basic fibroblast growth factor. Cancer Metastasis Rev, 9:191–202.
Johnson, D.E. and Williams, L.T., 1993, Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res, 60:1–41.
Ornitz, D.M., Xu, J., Colvin, J.S., McEwen, D.G., MacArthur, C.A., Coulier, F., Gao, G., and Goldfarb, M., 1996, Receptor specificity of the fibroblast growth factor family. J Biol Chem, 271:15292–15297.
Valve, E.M., Nevalainen, M.T., Nurmi, M.J., Laato, M.K., Martikainen, P.M., and Harkonen, P.L., 2001, Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer. Lab Invest, 81:815–826.
Dell'Era, P., Mohammadi, M., and Presta, M., 1999, Different tyrosine autophosphorylation requirements in fibroblast growth factor receptor-1 mediate urokinase-type plasminogen activator induction and mitogenesis. Mol Biol Cell, 10:23–33.
Spivak-Kroizman, T., Lemmon, M.A., Dikic, I., Ladbury, J.E., Pinchasi, D., Huang, J., Jaye, M., Crumley, G., Schlessinger, J., and Lax, I., 1994, Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell, 79:1015–1024.
Friesel, R.E. and Maciag, T., 1995, Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J, 9:919–925.
Xing, J., Ginty, D.D., and Greenberg, M.E., 1996, Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science, 273:959–963.
Tan, Y., Ruan, H., Demeter, M.R., and Comb, M.J., 1999, p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. J Biol Chem, 274:34859–34867.
Shimamura, A., Ballif, B.A., Richards, S.A., and Blenis, J., 2000, Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr Biol, 10:127–135.
Zong, W.X., Edelstein, L.C., Chen, C., Bash, J., and Gelinas, C., 1999, The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev., 13:382–387.
Ghoda, L., Lin, X., and Greene, W.C., 1997, The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. J Biol Chem, 272 21281–21288.
Bertolotto, C., Maulon, L., Filippa, N., Baier, G., and Auberger, P., 2000, Protein kinase C theta and epsilon promote T-cell survival by a rsk-dependent phosphorylation and inactivation of BAD. J Biol Chem, 275:37246–37250.
Delehedde, M., Seve, M., Sergeant, N., Wartelle, I., Lyon, M., Rudland, P.S., and Fernig, D.G., 2000, Fibroblast growth factor-2 stimulation of p42/44MAPK phosphorylation and IkappaB degradation is regulated by heparan sulfate/heparin in rat mammary fibroblasts. J Biol Chem, 275:33905–33910.
Du, K., and Montminy, M., 1998, CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem, 273:32377–32379.
Chen, C., Edelstein, L.C., and Gelinas, C., 2000, The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol, 20:2687–2695.
Bonni, A., Brunet, A., West, A.E., Datta, S.R., Takasu, M.A., and Greenberg, M.E., 1999, Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and-independent mechanisms. Science, 286:1358–1362.
Cardone, M.H., Roy, N., Stennicke, H.R., Salvesen, G.S., Franke, T.F., Stanbridge, E., Frisch, S., and Reed, J.C., 1998, Regulation of cell death protease caspase-9 by phosphorylation. Science, 282:1318–1321.
Fenig, E., Wieder, R., Paglin, S., Wang, H., Persaud, R., Haimovitz-Friedman, A., Fuks, Z., and Yahalom, J., 1997, Basic fibroblast growth factor confers growth inhibition and mitogen-activated protein kinase activation in human breast cancer cells. Clin Cancer Res, 3:135–142.
Wang, H., Rubin, M., Fenig, E., DeBlasio, A., Mendelsohn, J., Yahalom, J., and Wieder, R., 1997, Basic fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events. Cancer Res, 57:1750–1757.
Schweigerer, L., Neufeld, G., and Gospodarowicz, D., 1987, Basic fibroblast growth factor as a growth inhibitor for cultured human tumor cells. J Clin Ivest, 80:1516–1520.
Coleman, A.B., 2003, Positive and negative regulation of cellular sensitivity to anti-cancer drugs by FGF-2. Drug Resist Updat, 6:85–94.
Huang, A., Jin, H., and Wright, J.A., 1994, Aberrant expression of basic fibroblast growth factor in NIH-3T3 cells alters drug resistance and gene amplification potential. Exp Cell Res, 213:335–339.
Huang, A. and Wright, J.A., 1994, Fibroblast growth factor mediated alterations in drug resistance, and evidence of gene amplification. Oncogene, 9:491–499.
Linderholm, B.K., Lindh, B., Beckman, L., Erlanson, M., Edin, K., Travelin, B., Bergh, J., Grankvist, K., and Henriksson, R., 2003, Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer, 4:340–347.
Smith, K., Fox, S.B., Whitehouse, R., Taylor, M., Greenall, M., Clarke, J., and Harris, A.L., 1999, Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann Oncol, 10:707–713.
Blanckaert, V.D., Hebbar, M., Louchez, M.M., Vilain, M.O., Schelling, M.E., and Peyrat, J.P., 1998, Basic fibroblast growth factor receptors and their prognostic value in human breast cancer. Clin Cancer Res, 4:2939–2947.
Colomer, R., Aparicio, J., Montero, S., Guzman, C., Larrodera, L., and Cortes-Funes, H., 1997, Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer, 76:1215–1220.
Yiangou, C., Gomm, J.J., Coope, R.C., Law, M., Luqmani, Y.A., Shousha, S., Coombes, R. C., and Johnston, C.L., 1997, Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Br J Cancer, 75:28–33.
Obermair, A., Speiser, P., Reisenberger, K., Ullrich, R., Czerwenka, K., Kaider, A., Zeillinger, R., and Miksche, M., 1998, Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. Cancer Lett, 130:69–76.
Bredel, M., Pollack, I.F., Campbell, J.W., and Hamilton, R.L., 1997, Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas. Clin Cancer Res, 3:2157–2164.
Faridi, A., Rudlowski, C., Biesterfeld, S., Schuh, S., Rath, W., and Schroder, W., 2002, Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer. Pathol Res Pract, 198:1–5.
Tabone, M.D., Landman-Parker, J., Arcil, B., Coudert, M.C., Gerota, I., Benbunan, M., Leverger, G., and Dosquet, C., 2001, Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?. Clin Cancer Res, 7:538–543.
Nguyen, M., Watanabe, H., Budson, A.E., Richie, J.P., Hayes, D.F., and Folkman, J., 1994, Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst, 86:356–361.
Iwasaki, A., Kuwahara, M., Yoshinaga, Y., and Shirakusa, T., 2004, Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg, 25:443–448.
Ruotsalainen, T., Joensuu, H., Mattson, K., and Salven, P., 2002, High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Edpdemiol Biomarkers Prev, 11:1492–1495.
Joensuu, H., Anttonen, A., Eriksson, M., Makitaro, R., Alfthan, H., Kinnula, V., and Leppa, S., 2002, Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res, 62:5210–5217.
Ito, H., Oshita, F., Kameda, Y., Suzuki, R., Ikehara, M., Arai, H., Mitsuda, A., Saito, H., Yamada, K., Noda, K., and Nakayama, H., 2002, Expression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomas. Oncol Rep, 9:119–123.
Kos, M. and Dabrowski, A., 2002, Tumour's angiogenesis—the function of VEGF and bFGF in colorectal cancer. Ann Univ Mariae Curie Sklodowska [Med], 57:556–561.
Rasmuson, T., Grankvist, K., Jacobsen, J., and Ljungberg, B., 2001, Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. Eur J Cancer, 37:2199–2203.
Dietz, A., Rudat, V., Conradt, C., Weidauer, H., Ho, A., and Moehler, T., 2000, Prognostic relevance of serum levels of the angiogenic peptide bFGF in advanced carcinoma of the head and neck treated by primary radiochemotherapy. Head Neck, 22:666–673.
Anzai, H., Kitadai, Y., Bucana, C.D., Sanchez, R., Omoto, R., and Fidler, I.J., 1998, Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence. Eur J Cancer, 34:558–565.
Noda, M., Hattori, T., Kimura, T., Naitoh, H., Kodama, T., Kashima, K., and Pignatelli, M. 1997, Expression of fibroblast growth factor 2 mRNA in early and advanced gastric cancer. Acta Oncol, 36:695–700.
Pazgal, I., Zimra, Y., Tzabar, C., Okon, E., Rabizadeh, E., Shaklai, M., and Bairey, O., 2002, Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma. Br J Cancer, 86:1770–1775.
Salven, P., Orpana, A., Teerenhovi, L., and Joensuu, H., 2000, Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood, 96:3712–3718.
Tanaka, S., Ueo, H., Mafune, K., Mori, M., Wands, J.R., and Sugimachi, K., 2001, A novel isoform of human fibroblast growth factor 8 is induced by androgens and associated with progression of esophageal carcinoma. Dig Dis Sci, 46:1016–1021.
Boelaert, K., McCabe, C.J., Tannahill, L.A., Gittoes, N.J., Holder, R.L., Watkinson, J.C., Bradwell, A.R., Sheppard, M.C., and Franklyn, J.A., 2003, Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab, 88:2341–2347.
Sun, Y., Naito, Z., Ishiwata, T., Maeda, S., Sugisaki, Y., and Asano, G., 2003, Basic FGF and Ki-67 proteins useful for immunohistological diagnostic evaluations in malignant solitary fibrous tumor. Pathol Int, 53:284–290.
Strizzi, L., Vianale, G., Catalano, A., Muraro, R., Mutti, L., and Procopio, A., 2001, Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int J Oncol, 18:1093–1098.
Lin, R.Y., Argenta, P.A., Sullivan, K.M., and Adzick, N.S., 1995, Diagnostic and prognostic role of basic fibroblast growth factor in Wilms’ tumor patients. Clin Cancer Res, 1:327–331.
Ohta, T., Yamamoto, M., Numata, M., Iseki, S., Tsukioka, Y., Miyashita, T., Kayahara, M., Nagakawa, T., Miyazaki, I., Nishikawa, K., and Yoshitake, Y., 1995, Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas. Br J Cancer, 72:824–831.
Volm, M., Koomagi, R., Mattern, J., and Stammler, G., 1997, Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur J Cancer, 33:691–693.
Bange, J., Prechtl, D., Cheburkin, Y., Specht, K., Harbeck, N., Schmitt, M., Knyazeva, T., Muller, S., Gartner, S., Sures, I., Wang, H., Imyanitov, E., Haring, H.U., Knayzev, P., Iacobelli, S., Hofler, H., and Ullrich, A., 2002, Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res, 62:840–847.
Morimoto, Y., Ozaki, T., Ouchida, M., Umehara, N., Ohata, N., Yoshida, A., Shimizu, K., and Inoue, H., 2003, Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer, 98:2245–2250.
Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J.P., and Radvanyi, F., 1999, Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet, 23:18–20.
Ueno, K., Inoue, Y., Kawaguchi, T., Hosoe, S., and Kawahara, M., 2001, Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer, 31:213–219.
Pardo, O.E., Arcaro, A., Salerno, G., Raguz, S., Downward, J., and Seckl, M.J., 2002, Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem, 277:12040–12046.
Pardo, O.E., Lesay, A., Arcaro, A., Lopes, R., Ng, B.L., Warne, P.H., McNeish, I.A., Tetley, T.D., Lemoine, N.R., Mehmet, H., Seckl, M.J., and Downward, J., 2003, Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. Mol Cell Biol, 23:7600–7610.
Shaulian, E., Resnitzky, D., Shifman, O., Blandino, G., Amsterdam, A., Yayon, A., and Oren, M., 1997, Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene, 15:2717–2725.
Maloof, P., Wang, Q., Wang, H., Stein, D., Denny, T.N., Yahalom, J., Fenig, E., and Wieder, R., 1999, Overexpression of basic fibroblast growth factor (FGF-2) downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. Breast Cancer Res Treat, 56:153–167.
Wang, Q., Maloof, P., Wang, H., Fenig, E., Stein, D., Nichols, G., Denny, T.N., Yahalom, J., and Wieder, R., 1998, Basic fibroblast growth factor downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. Exp Cell Res, 238:177–187.
Bisping, G., Leo, R., Wenning, D., Dankbar, B., Padro, T., Kropff, M., Scheffold, C., Kroger, M., Mesters, R.M., Berdel, W.E., and Kienast, J., 2003, Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood, 101:2775–2783.
El Hariry, I., Pignatelli, M., and Lemoine, N., 2001, R. FGF-1 and FGF-2 regulate the expression of E-cadherin and catenins in pancreatic adenocarcinoma. Int J Cancer, 94:652–661.
El Hariry, I., Pignatelli, M., and Lemoine, N. R., 2001, FGF-1 and FGF-2 modulate the E-cadherin/catenin system in pancreatic adenocarcinoma cell lines. Br J Cancer, 84:1656–1663.
Qiao, D., Meyer, K., Mundhenke, C., Drew, S. A., and Friedl, A., 2003, Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial cells. Specific role for glypican-1 in glioma angiogenesis. J Biol Chem, 278:16045–16053.
Mundhenke, C., Meyer, K., Drew, S., and Friedl, A., 2002, Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol, 160:185–194.
Lambrecht, V., Le, B., X, Toillon, R.A., Boilly, B., and Hondermarck, H., 1998, Alterations in both heparan sulfate proteoglycans and mitogenic activity of fibroblast growth factor-2 are triggered by inhibitors of proliferation in normal and breast cancer epithelial cells. Exp Cell Res, 245:239–244.
Delehedde, M., Deudon, E., Boilly, B., and Hondermarck, H., 1996, Heparan sulfate proteoglycans play a dual role in regulating fibroblast growth factor-2 mitogenic activity in human breast cancer cells. Exp Cell Res, 229:398–406.
Genersch, E., Ferletta, M., Virtanen, I., Haller, H., and Ekblom, P., 2003, Integrin alphavbeta3 binding to human alpha5-laminins facilitates FGF-2-and VEGF-induced proliferation of human ECV304 carcinoma cells. Eur J Cell Biol, 82:105–117.
De Medina, S.G., Popov, Z., Chopin, D.K., Southgate, J., Tucker, G.C., Delouvee, A., Thiery, J.P., and Radvanyi, F., 1999, Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas. Oncogene, 18:5722–5726.
Cavallaro, U., Niedermeyer, J., Fuxa, M., and Christofori, G., 2001, N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol, 3:650–657.
Boyer, B., Dufour, S., and Thiery, J.P., 1992, E-cadherin expression during the acidic FGF-induced dispersion of a rat bladder carcinoma cell line. Exp Cell Res, 201:347–357.
Zhang, Y., Song, S., Yang, F., Au, J.L., and Wientjes, M.G., 2001, Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther, 299:426–433.
Song, S., Wientjes, M.G., Walsh, C., and Au, J.L., 2001, Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res, 61:6145–6150.
Xin Y., Chen D., Song S., Lyness G., Wientjes G., and Au J., 2004, Low-dose suramin enhances antitumor activity of mitomycin C in bladder tumors. [Abstract]. Proceedings of the AACR, 45:#2002.
Ogden A., Song S., Wientjes G., and Au J., 2004, Nontoxic doses of suramin enhance the activity of gemcitabine and paclitaxel in pancreatic tumors. [Abstract]. Proceedings of the AACR, 45:#2148.
Yu B., Song S., Wientjes G., and Au J., 2003, Suramin enhances activity of CPT-11 in human colorectal xenograft tumors [Abstract]. Proceedings of the AACR, 44:#763.
Lyness G., Jang S., Gan Y., Zhang Y., Wientjes G., and Au J., 2003, Fibroblast growth factors and chemoresistance in renal cell carcinomas [Abstract]. Proceedings of the AACR, 44:#4718.
Villalona-Calero M.A., Otterson G.A., Wientjes G., Kobayashi K., Jensen R., Young D., Yeh T., Song S., Grever M., and Au J., 2004, Phase II study of low dose suramin as a sensitizer of paclitaxel/carboplatin (P/C) in non small cell lung cancer (NSCLC). [Abstract]. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 22:#7108.
Yu, H., and Rohan, T., 2000, Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92:1472–1489.
LeRoith, D. and Roberts, Jr., C.T., 2003, The insulin-like growth factor system and cancer. Cancer Lett, 195:127–137.
Samani, A.A., and Brodt, P., 2001, The receptor for the type I insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis. Surg Oncol Clin N Am, 10:289–312,viii.
Lee, A.V., Hilsenbeck, S.G., and Yee, D., 1998, IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat, 47:295–302.
Kaaks, R. 2002. Nutrition, energy balance and colon cancer risk: the role of insulin and insulin-like growth factor-I. IARC Sci Publ, 156:289–293.
Chan, J.M., Stampfer, M.J., Giovannucci, E., Ma, J., and Pollak, M., 2000, Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies. Growth Horm IGF Res, 10Suppl A:S32–S33.
Giovannucci, E., 1999, Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res, 51Suppl3:34–41.
Spitz, M.R., Barnett, M.J., Goodman, G.E., Thornquist, M.D., Wu, X., and Pollak, M., 2002, Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Edpdemiol Biomarkers Prev, 11:1413–1418.
Schernhammer, E.S., 2002, In-utero exposures and breast cancer risk: joint effect of estrogens and insulin-like growth factor? Cancer Causes Control, 13:505–508.
Pollak, M., 2000, Insulin-like growth factor physiology and cancer risk. Eur J Cancer, 36:1224–1228.
Baron-Hay, S., Boyle, F., Ferrier, A., and Scott, C., 2004, Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res, 10:1796–1806.
Gu, L., Shigemasa, K., and Ohama, K., 2004, Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol, 24:671–678.
Peters, G., Gongoll, S., Langner, C., Mengel, M., Piso, P., Klempnauer, J., Ruschoff, J., Kreipe, H., and von Wasielewski, R., 2003, IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch, 443:139–145.
Kawamoto, K., Onodera, H., Kondo, S., Kan, S., Ikeuchi, D., Maetani, S., and Imamura, M., 1998, Expression of insulin-like growth factor-2 can predict the prognosis of human colorectal cancer patients: correlation with tumor progression, proliferative activity and survival. Oncology, 55:242–248.
Jamieson, T.A., Brizel, D.M., Killian, J.K., Oka, Y., Jang, H.S., Fu, X., Clough, R.W., Vollmer, R.T., Anscher, M.S., and Jirtle, R.L., 2003, M6P/IGF2R loss of heterozygosity in head and neck cancer associated with poor patient prognosis. BMC Cancer, 3:4.
Chang, Y.S., Wang, L., Liu, D., Mao, L., Hong, W.K., Khuri, F.R., and Lee, H.Y., 2002, Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res, 8:3669–3675.
Standal, T., Borset, M., Lenhoff, S., Wisloff, F., Stordal, B., Sundan, A., Waage, A., and Seidel, C., 2002, Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood, 100:3925–3929.
Rocha, R.L., Hilsenbeck, S.G., Jackson, J.G., Lee, A.V., Figueroa, J.A., and Yee, D., 1996, Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst, 88:601–606.
Holdaway, I.M., Mason, B.H., Lethaby, A.E., Singh, V., Harvey, V.J., Thompson, P.I., and Evans, B.D., 2003, Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer. ANZ J Surg, 73:905–908.
Railo, M.J., von Smitten, K., and Pekonen, F., 1994, The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer, 30A:307–311.
Bonneterre, J., Peyrat, J.P., Beuscart, R., and Demaille, A., 1990, Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res, 50:6931–6935.
Turner, B.C., Haffty, B.G., Narayanan, L., Yuan, J., Havre, P.A., Gumbs, A.A., Kaplan, L., Burgaud, J.L., Carter, D., Baserga, R., and Glazer, P.M., 1997, Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res, 57:3079–3083.
Takanami, I., Imamuma, T., Hashizume, T., Kikuchi, K., Yamamoto, Y., Yamamoto, T., and Kodaira, S., 1996, Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma. J Surg Oncol, 61:205–208.
Grothey, A., Voigt, W., Schober, C., Muller, T., Dempke, W., and Schmoll, H.J., 1999, The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol, 125:166–173.
Hadsell, D.L. and Abdel-Fattah, G., 2001, Regulation of cell apoptosis by insulin-like growth factor I. Adv Exp Med Biol, 501:79–85.
Vincent, A.M. and Feldman, E.L. 2002. Control of cell survival by IGF signaling pathways. Growth Horm IGF Res, 12:193–197.
Le Roith, D., 2000, Regulation of proliferation and apoptosis by the insulin-like growth factor I receptor. Growth Horm IGF Res, 10SupplA:S12–S13.
Isgaard, J., and Tivesten, A., 1999, The role of growth hormone and insulin-like growth factor I in the regulation of apoptosis. Growth Horm IGF Res, 9SupplA:125–128.
Garrouste, F., Remacle-Bonnet, M., Fauriat, C., Marvaldi, J., Luis, J., and Pommier, G., 2002, Prevention of cytokine-induced apoptosis by insulin-like growth factor-I is independent of cell adhesion molecules in HT29-D4 colon carcinoma cells-evidence for a NF-kappaB-dependent survival mechanism. Cell Death Differ, 9:768–779.
Gil-Ad, I., Shtaif, B., Luria, D., Karp, L., Fridman, Y., and Weizman, A., 1999, Insulin-like-growth-factor-I (IGF-I) antagonizes apoptosis induced by serum deficiency and doxorubicin in neuronal cell culture. Growth Horm IGF Res, 9:458–464.
Geier, A., Hemi, R., Haimsohn, M., Beery, R., Malik, Z., and Karasik, A., 1994, Epidermal growth factor and insulin-like growth factor-1 protect MDA-231 cells from death induced by actinomycin D: the involvement of growth factors in drug resistance. In Vitro Cell Dev Biol Anim, 30A:336–343.
Gooch, J.L., Van Den Berg, C.L., and Yee, D., 1999, Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death—proliferative and anti-apoptotic effects. Breast Cancer Res Treat, 56:1–10.
Guo, Y.S., Jin, G.F., Houston, C.W., Thompson, J.C., and Townsend, Jr., C.M., 1998, Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells. J Cell Physiol, 175:141–148.
Sekharam, M., Zhao, H., Sun, M., Fang, Q., Zhang, Q., Yuan, Z., Dan, H.C., Boulware, D., Cheng, J.Q., and Coppola, D., 2003, Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res, 63:7708–7716.
Levitt, R.J. and Pollak, M., 2002, Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Res, 62:7372–7376.
Liu, Y.C., Leu, C.M., Wong, F.H., Fong, W.S., Chen, S.C., Chang, C., and Hu, C.P., 2002, Autocrine stimulation by insulin-like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells. J Biomed Sci, 9:665–674.
Wan, X. and Helman, L.J., 2002, Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. Neoplasia, 4:400–408.
Sun, H.Z., Wu, S.F., and Tu, Z.H., 2001, Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity. Cell Res, 11:107–115.
Butt, A.J., Firth, S.M., and Baxter, R.C., 1999, The IGF axis and programmed cell death. Immunol Cell Biol, 77:256–262.
Werner, H. and Le Roith, D., 1997, The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog, 8:71–92.
Bohula, E.A., Playford, M.P., and Macaulay, V.M., 2003, Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs, 14:669–682.
Salisbury, A.J. and Macaulay, V.M., 2003, Development of molecular agents for IGF receptor targeting. Horm Metab Res, 35:843–849.
Andrews, D.W., Resnicoff, M., Flanders, A.E., Kenyon, L., Curtis, M., Merli, G., Baserga, R., Iliakis, G., and Aiken, R.D., 2001, Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol, 19:2189–2200.
Liu, X., Turbyville, T., Fritz, A., and Whitesell, L., 1998, Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res, 58:5432–5438.
Birchmeier, C., Birchmeier, W., Gherardi, E., and Vande Woude, G.F., 2003, Met, metastasis, motility and more. Nat.Rev.Mol Cell Biol, 4:915–925.
Zhang, Y.W. and Vande Woude, G.F., 2003, HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem, 88:408–417.
Danilkovitch-Miagkova, A. and Zbar, B., 2002, Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest, 109:863–867.
Haddad, R., Lipson, K.E., and Webb, C.P., 2001, Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors. AntiCancer Res, 21:4243–4252.
Trusolino, L. and Comoglio, P.M., 2002, Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer, 2:289–300.
Birchmeier, C. and Gherardi, E., 1998, Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol, 8:404–410.
Vadnais, J., Nault, G., Daher, Z., Amraei, M., Dodier, Y., Nabi, I. R., and Noel, J., 2002, Autocrine activation of the hepatocyte growth factor receptor/met tyrosine kinase induces tumor cell motility by regulating pseudopodial protrusion. J Biol Chem, 277:48342–48350.
Yi, S. and Tsao, M.S., 2000, Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia, 2:226–234.
Jeffers, M., Rong, S., Anver, M., and Vande Woude, G.F., 1996, Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells. Oncogene, 13:853–856.
Tsao, M.S., Yang, Y., Marcus, A., Liu, N., and Mou, L., 2001, Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. Hum Pathol, 32:57–65.
Chen, Y.S., Wang, J.T., Chang, Y.F., Liu, B.Y., Wang, Y.P., Sun, A., and Chiang, C.P., 2004, Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan. J Oral Pathol Med, 33:209–217.
Parr, C., Watkins, G., Mansel, R.E., and Jiang, W.G., 2004, The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res, 10:202–211.
Nardone, H.C., Ziober, A.F., LiVolsi, V.A., Mandel, S.J., Baloch, Z.W., Weber, R.S., Mick, R., and Ziober, B.L., 2003, c-Met expression in tall cell variant papillary carcinoma of the thyroid. Cancer, 98:1386–1393.
Takeuchi, H., Bilchik, A., Saha, S., Turner, R., Wiese, D., Tanaka, M., Kuo, C., Wang, H.J., and Hoon, D.S., 2003, c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res, 9:1480–1488.
Tolgay, O., I, Dolled-Filhart, M., D'Aquila, T.G., Camp, R.L., and Rimm, D.L., 2003, Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer, 97:1841–1848.
Maulik, G., Shrikhande, A., Kijima, T., Ma, P. C., Morrison, P.T., and Salgia, R., 2002, Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev, 13:41–59.
Furukawa, T., Duguid, W.P., Kobari, M., Matsuno, S., and Tsao, M.S., 1995, Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am J Pathol, 147:889–895.
Baykal, C., Ayhan, A., Al, A., Yuce, K., and Ayhan, A., 2003, Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecol Oncol, 88:123–129.
Gohji, K., Nomi, M., Niitani, Y., Kitazawa, S., Fujii, A., Katsuoka, Y., and Nakajima, M., 2000, Independent prognostic value of serum hepatocyte growth factor in bladder cancer. J Clin Oncol, 18:2963–2971.
Tsarfaty, I., Alvord, W.G., Resau, J.H., Altstock, R.T., Lidereau, R., Bieche, I., Bertrand, F., Horev, J., Klabansky, R.L., Keydar, I., and Vande Woude, G.F., 1999, Alteration of Met protooncogene product expression and prognosis in breast carcinomas. Anal.Quant.Cytol.Histol., 21:397–408.
Nakajima, M., Sawada, H., Yamada, Y., Watanabe, A., Tatsumi, M., Yamashita, J., Matsuda, M., Sakaguchi, T., Hirao, T., and Nakano, H., 1999, The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer, 85:1894–1902.
Porte, H., Triboulet, J.P., Kotelevets, L., Carrat, F., Prevot, S., Nordlinger, B., DiGioia, Y., Wurtz, A., Comoglio, P., Gespach, C., and Chastre, E., 1998, Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. Clin Cancer Res, 4:1375–1382.
Tokunou, M., Niki, T., Eguchi, K., Iba, S., Tsuda, H., Yamada, T., Matsuno, Y., Kondo, H., Saitoh, Y., Imamura, H., and Hirohashi, S., 2001, c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma. Am J Pathol, 158:1451–1463.
Cheng, H.L., Trink, B., Tzai, T.S., Liu, H.S., Chan, S.H., Ho, C.L., Sidransky, D., and Chow, N.H., 2002, Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol, 20:1544–1550.
Rasola, A., Anguissola, S., Ferrero, N., Gramaglia, D., Maffe, A., Maggiora, P., Comoglio, P.M., and Di Renzo, M.F., 2004, Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res, 64:1744–1750.
Bowers, D.C., Fan, S., Walter, K.A., Abounader, R., Williams, J.A., Rosen, E.M., and Laterra, J., 2000, Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase-and AKT-dependent pathways. Cancer Res, 60:4277–4283.
Aebersold, D.M., Kollar, A., Beer, K.T., Laissue, J., Greiner, R.H., and Djonov, V., 2001, Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer, 96:41–54.
Jankowski, K., Kucia, M., Wysoczynski, M., Reca, R., Zhao, D., Trzyna, E., Trent, J., Peiper, S., Zembala, M., Ratajczak, J., Houghton, P., Janowska-Wieczorek, A., and Ratajczak, M.Z., 2003, Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res, 63:7926–7935.
Wang, X., Zhou, Y., Kim, H.P., Song, R., Zarnegar, R., Ryter, S.W., and Choi, A.M., 2004, Hepatocyte growth factor protects against hypoxia/reoxygenation-induced apoptosis in endothelial cells. J Biol Chem, 279:5237–5243.
Derksen, P.W., de Gorter, D.J., Meijer, H.P., Bende, R.J., van Dijk, M., Lokhorst, H.M., Bloem, A.C., Spaargaren, M., and Pals, S.T., 2003, The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia, 17:764–774.
Nakagami, H., Morishita, R., Yamamoto, K., Taniyama, Y., Aoki, M., Yamasaki, K., Matsumoto, K., Nakamura, T., Kaneda, Y., and Ogihara, T., 2002, Hepatocyte growth factor prevents endothelial cell death through inhibition of bax translocation from cytosol to mitochondrial membrane. Diabetes, 51:2604–2611.
Ma, H., Calderon, T.M., Fallon, J.T., and Berman, J.W., 2002, Hepatocyte growth factor is a survival factor for endothelial cells and is expressed in human atherosclerotic plaques. Atherosclerosis, 164:79–87.
Gao, M., Fan, S., Goldberg, I.D., Laterra, J., Kitsis, R.N., and Rosen, E.M., 2001, Hepatocyte growth factor/scatter factor blocks the mitochondrial pathway of apoptosis signaling in breast cancer cells. J Biol Chem, 276:47257–47265.
Fan, S., Ma, Y.X., Gao, M., Yuan, R.Q., Meng, Q., Goldberg, I.D., and Rosen, E.M., 2001, The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair. Mol Cell Biol, 21:4968–4984.
Aebersold, D.M., Kollar, A., Beer, K.T., Laissue, J., Greiner, R.H., and Djonov, V., 2001, Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer, 96:41–54.
Fan, S., Ma, Y.X., Wang, J.A., Yuan, R.Q., Meng, Q., Cao, Y., Laterra, J.J., Goldberg, I.D., and Rosen, E.M., 2000, The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3′ kinase. Oncogene, 19:2212–2223
Date, K., Matsumoto, K., Shimura, H., Tanaka, M., and Nakamura, T., 1997, HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett, 420: 1–6
Dranoff, G., 2004, Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer, 4:11–22.
Cohen, Jr., M.M., 2003, TGF beta/Smad signaling system and its pathologic correlates. Am.J Med.Genet., 116A:1–10.
Cordeiro, M.F., 2002, Beyond Mitomycin: TGF-beta and wound healing. Prog Retin Eye Res, 21:75–89.
Moustakas, A., Pardali, K., Gaal, A., and Heldin, C.H., 2002, Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett, 82:85–91.
Siegel, P.M. and Massague, J., 2003, Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer, 3:807–821.
Verrecchia, F. and Mauviel, A., 2002, Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol, 118:211–215.
Massague, J., Blain, S.W., and Lo, R.S., 2000, TGFbeta signaling in growth control, cancer, and heritable disorders. Cell, 103:295–309.
Derynck, R., Akhurst, R.J., and Balmain, A., 2001, TGF-beta signaling in tumor suppression and cancer progression. Nat Genet, 29:117–129.
Derynck, R. and Zhang, Y.E., 2003, Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 425:577–584.
Massague, J., 2000, How cells read TGF-beta signals. Nat Rev Mol Cell Biol, 1:169–178.
Massague, J., 1998, TGF-beta signal transduction. Annu Rev Biochem, 67:753–791.
Shibuya, H., Yamaguchi, K., Shirakabe, K., Tonegawa, A., Gotoh, Y., Ueno, N., Irie, K., Nishida, E., and Matsumoto, K., 1996, TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science, 272:1179–1182.
Yue, J., and Mulder, K.M., 2000, Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a smad-dependent pathway. J Biol Chem, 275:35656.
Park, B.J., Park, J.I., Byun, D.S., Park, J.H., and Chi, S.G., 2000, Mitogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. Cancer Res, 60:3031–3038.
Mulder, K.M., 2000, Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth Factor Rev, 11:23–35.
Kivinen, L., and Laiho, M., 1999, Ras-and mitogen-activated protein kinase kinase-dependent and-independent pathways in p21Cip1/Waf1 induction by fibroblast growth factor-2, platelet-derived growth factor, and transforming growth factor-beta1. Cell Growth Differ, 10:621–628.
Yamamoto, H., Atsuchi, N., Tanaka, H., Ogawa, W., Abe, M., Takeshita, A., and Ueno, H., 1999, Separate roles for H-Ras and Rac in signaling by transforming growth factor (TGF)-beta. H-Ras is essential for activation of MAP kinase, partially required for transcriptional activation by TGF-beta, but not required for signaling of growth suppression by TGF-beta. Eur.J Biochem., 264:110–119.
Reimann, T., Hempel, U., Krautwald, S., Axmann, A., Scheibe, R., Seidel, D., and Wenzel, K.W., 1997, Transforming growth factor-beta1 induces activation of Ras, Raf-1, MEK and MAPK in rat hepatic stellate cells. FEBS Lett, 403:57–60.
Atfi, A., Djelloul, S., Chastre, E., Davis, R., and Gespach, C., 1997, Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling. J Biol Chem, 272:1429–1432.
Petritsch, C., Beug, H., Balmain, A., and Oft, M., 2000, TGF-beta inhibits p70 S6 kinase via protein phosphatase 2A to induce G(1) arrest. Genes Dev, 14:3093–3101.
Griswold-Prenner, I., Kamibayashi, C., Maruoka, E.M., Mumby, M.C., and Derynck, R., 1998, Physical and functional interactions between type I transforming growth factor beta receptors and Balpha, a WD-40 repeat subunit of phosphatase 2A. Mol Cell Biol, 18:6595–6604.
Horowitz, J.C., Lee, D.Y., Waghray, M., Keshamouni, V.G., Thomas, P.E., Zhang, H., Cui, Z., and Thannickal, V.J., 2004, Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J Biol Chem, 279:1359–1367.
Shin, I., Bakin, A.V., Rodeck, U., Brunet, A., and Arteaga, C.L., 2001, Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell, 12:3328–3339.
Wakefield, L.M. and Roberts, A.B., 2002, TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev, 12:22–29.
Sun, L., 2004, Tumor-suppressive and promoting function of transforming growth factor beta. Front Biosci, 9:1925–1935.
Roberts, A.B. and Wakefield, L.M., 2003, The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA, 100:8621–8623.
Wikstrom, P., Stattin, P., Franck-Lissbrant, I., Damber, J.E., and Bergh, A. 1998, Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate, 37:19–29.
Eastham, J.A., Truong, L.D., Rogers, E., Kattan, M., Flanders, K.C., Scardino, P.T., and Thompson, T.C., 1995, Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest, 73:628–635.
Steiner, M.S., Zhou, Z.Z., Tonb, D.C., and Barrack, E.R., 1994, Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology, 135:2240–2247.
Muir, G.H., Butta, A., Shearer, R.J., Fisher, C., Dearnaley, D.P., Flanders, K.C., Sporn, M.B., and Colletta, A.A., 1994, Induction of transforming growth factor beta in hormonally treated human prostate cancer. Br J, Cancer, 69:130–134.
Knabbe, C., Klein, H., Zugmaier, G., and Voigt, K.D., 1993, Hormonal regulation of transforming growth factor beta-2 expression in human prostate cancer. J Steroid Biochem Mol Biol, 47:137–142.
Truong, L.D., Kadmon, D., McCune, B.K., Flanders, K.C., Scardino, P.T., and Thompson, T.C., 1993, Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol, 24:4–9.
Wikstrom, P., Damber, J., and Bergh, A., 2001, Role of transforming growth factor-beta1 in prostate cancer. Microsc Res Tech, 52:411–419.
Kim, I.Y., Ahn, H.J., Lang, S., Oefelein, M.G., Oyasu, R., Kozlowski, J.M., and Lee, C., 1998, Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res, 4:1625–1630.
Shariat, S.F., Menesses-Diaz, A., Kim, I.Y., Muramoto, M., Wheeler, T.M., and Slawin, K.M., 2004, Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology, 63:1191–1197.
Wikstrom, P., Bergh, A., and Damber, J.E., 2000, Transforming growth factor-beta1 and prostate cancer. Scand J Urol Nephrol, 34:85–94.
MacCallum, J., Bartlett, J.M., Thompson, A.M., Keen, J.C., Dixon, J.M., and Miller, W.R., 1994, Expression of transforming growth factor beta mRNA isoforms in human breast cancer. Br J Cancer, 69:1006–1009.
Auvinen, P., Lipponen, P., Johansson, R., and Syrjanen, K., 1995, Prognostic significance of TGF-beta 1 and TGF-beta 2 expressions in female breast cancer. AntiCancer Res, 15:2627–2631.
Kong, F.M., Anscher, M.S., Murase, T., Abbott, B.D., Iglehart, J.D., and Jirtle, R.L., 1995, Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg, 222:155–162.
Auvinen, P., Lipponen, P., Johansson, R., and Syrjanen, K., 1995, Prognostic significance of TGF-beta 2 expression in female breast cancer. Eur J Cancer, 31A: 851.
Thompson, A.M., Kerr, D.J., and Steel, C.M., 1991, Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer. Br J Cancer, 63:609–614.
Ghellal, A., Li, C., Hayes, M., Byrne, G., Bundred, N., and Kumar, S., 2000, Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma. AntiCancer Res, 20:4413–4418.
Hasegawa, Y., Takanashi, S., Kanehira, Y., Tsushima, T., Imai, T., and Okumura, K., 2001, Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer, 91:964–971.
Saji, H., Nakamura, H., Awut, I., Kawasaki, N., Hagiwara, M., Ogata, A., Hosaka, M., Saijo, T., Kato, Y., and Kato, H., 2003, Significance of expression of TGF-beta in pulmonary metastasis in non-small cell lung cancer tissues. Ann Thorac Cardiovasc Surg, 9:295–300.
Gold, L.I., 1999, The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog, 10:303–360.
Bennett, W.P., el Deiry, W.S., Rush, W.L., Guinee, Jr., D.G., Freedman, A.N., Caporaso, N.E., Welsh, J.A., Jones, R.T., Borkowski, A., Travis, W.D., Fleming, M.V., Trastek, V., Pairolero, P.C., Tazelaar, H.D., Midthun, D., Jett, J.R., Liotta, L.A., and Harris, C.C., 1998, p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res, 4:1499–1506.
Takanami, I., Tanaka, F., Hashizume, T., and Kodaira, S., 1997, Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study. J Surg Oncol, 64:262–267.
Takanami, I., Tanaka, F., Hashizume, T., Kikuchi, K., Yamamoto, Y., Yamamoto, T., and Kodaira, S., 1997, Transforming growth factor-beta isoforms expressions in pulmonary adenocarcinomas as prognostic markers: an immunohistological study of one hundred and twenty patients. Oncology, 54:122–128.
de Jonge, R.R., Garrigue-Antar, L., Vellucci, V.F., and Reiss, M., 1997, Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells. Oncol Res, 9:89–98.
Takanami, I., Imamuma, T., Hashizume, T., Kikuchi, K., Yamamoto, Y., Yamamoto, T., and Kodaira, S., 1996, Expression of PDGF, IGF-II, bFGF and TGF-beta 1 in pulmonary adenocarcinoma. Pathol Res Pract, 192:1113–1120.
Takanami, I., Imamura, T., Hashizume, T., Kikuchi, K., Yamamoto, Y., and Kodaira, S., 1994, Transforming growth factor beta 1 as a prognostic factor in pulmonary adenocarcinoma. J Clin Pathol, 47:1098–1100.
Okumoto, K., Hattori, E., Tamura, K., Kiso, S., Watanabe, H., Saito, K., Saito, T., Togashi, H., and Kawata, S., 2004, Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int, 24:21–28.
Tsai, J.F., Chuang, L.Y., Jeng, J.E., Yang, M.L., Chang, W.Y., Hsieh, M.Y., Lin, Z.Y., and Tsai, J.H., 1997, Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma. Medicine (Baltimore), 76:213–226.
Tsai, J.F., Jeng, J.E., Chuang, L.Y., Yang, M.L., Ho, M.S., Chang, W.Y., Hsieh, M.Y., Lin, Z.Y., and Tsai, J.H., 1997, Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. Br J Cancer, 76:244–250.
Robson, H., Anderson, E., James, R.D., and Schofield, P.F., 1996, Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer, 74:753–758.
Saito, H., Tsujitani, S., Oka, S., Kondo, A., Ikeguchi, M., Maeta, M., and Kaibara, N., 1999, The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer, 86:1455–1462.
Nakamura, M., Katano, M., Kuwahara, A., Fujimoto, K., Miyazaki, K., Morisaki, T., and Mori, M., 1998, Transforming growth factor beta1 (TGF-beta1) is a preoperative prognostic indicator in advanced gastric carcinoma. Br J Cancer, 78:1373–1378.
Hulshof, M.C., Sminia, P., Barten-Van Rijbroek, A.D., and Gonzalez, G.D., 2001, Prognostic value of plasma transforming growth factor-beta in patients with glioblastoma multiforme. Oncol Rep, 8:1107–1110.
Buck, M.B., Fritz, P., Dippon, J., Zugmaier, G., and Knabbe, C., 2004, Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res, 10:491–498.
Fukai, Y., Fukuchi, M., Masuda, N., Osawa, H., Kato, H., Nakajima, T., and Kuwano, H., 2003, Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J Cancer, 104:161–166.
Xie, W., Bharathy, S., Kim, D., Haffty, B.G., Rimm, D.L., and Reiss, M., 2003, Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. Oncol Res, 14:61–73.
Xie, W., Rimm, D.L., Lin, Y., Shih, W.J., and Reiss, M., 2003, Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J, 9:302–312.
Fukuchi, M., Fukai, Y., Masuda, N., Miyazaki, T., Nakajima, M., Sohda, M., Manda, R., Tsukada, K., Kato, H., and Kuwano, H., 2002, High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res, 62:7162–7165.
Xie, W., Mertens, J.C., Reiss, D.J., Rimm, D.L., Camp, R.L., Haffty, B.G., and Reiss, M., 2002, Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res, 62:497–505.
Boulay, J.L., Mild, G., Lowy, A., Reuter, J., Lagrange, M., Terracciano, L., Laffer, U., Herrmann, R., and Rochlitz, C., 2002, SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. Br J, Cancer, 87:630–634.
Dickson, J., Davidson, S.E., Hunter, R.D., and West, C.M., 2000, Pretreatment plasma TGF beta 1 levels are prognostic for survival but not morbidity following radiation therapy of carcinoma of the cervix. Int J Radiat Oncol Biol Phys, 48:991–995.
Keyes, K., Cox, K., Treadway, P., Mann, L., Shih, C., Faul, M.M., and Teicher, B.A., 2002, An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res, 62:5597–5602.
Teicher, B.A., 2001, Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev, 20:133–143.
Liu, P., Menon, K., Alvarez, E., Lu, K., and Teicher, B.A., 2000, Transforming growth factor-beta and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo. Int J Oncol, 16:599–610.
Teicher, B.A., Ikebe, M., Ara, G., Keyes, S.R., and Herbst, R.S., 1997, Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. In Vivo, 11:463–472.
Teicher, B.A., Kakeji, Y., Ara, G., Herbst, R. S., and Northey, D., 1997, Prostate carcinoma response to cytotoxic therapy: in vivo resistance. In Vivo, 11:453–461.
Teicher, B.A., Maehara, Y., Kakeji, Y., Ara, G., Keyes, S.R., Wong, J., and Herbst, R., 1997, Reversal of in vivo drug resistance by the transforming growth factor-beta inhibitor decorin. Int J Cancer, 71:49–58.
Kakeji, Y., Maehara, Y., Ikebe, M., and Teicher, B.A. 1997 Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. Int.J Radiat.Oncol.BiolPhys., 37:1115–1123.
Teicher, B.A., Holden, S.A., Ara, G., and Chen, G. 1996. Transforming growth factor-beta in in vivo resistance. Cancer Chemother Pharmacol, 37:601–609.
Chen, G., Teicher, B.A., and Frei, III, E., 1998, Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype. Cancer Biochem Biophys, 16:139–155.
Teicher, B.A., Ara, G., Keyes, S.R., Herbst, R. S., and Frei, E., III 1998. Acute in vivo resistance in high-dose therapy. Clin Cancer Res, 4:483–491.
Chatterjee, D., Liu, C. J., Northey, D., and Teicher, B.A. 1995. Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors. Cancer Chemother Pharmacol, 35:423–431.
Kobayashi, H., Man, S., Graham, C.H. Kapitain, S. J., Teicher, B.A., and Kerbek, R.S., 1993, Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci, USA, 90:3294–3298.
Teicher, B.A., Chatterjee, D., Liu, J.T., Holden, S.A., and Ara, G., 1993, Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors. Cancer Chemother Pharmacol, 32:315–319.
Xu, Z., Ma, D. Z., Wang, L.Y., Su, J.M., and Zha, X.L., 2003, Transforming growth factor-beta1 stimulated protein kinase B serine-473 and focal adhesion kinase tyrosine phosphorylation dependent on cell adhesion in human hepatocellular carcinoma SMMC-7721 cells. Biochem Biophys Res Commun, 312:388–396.
Nakamura, E., Megumi, Y., Kobayashi, T., Kamoto, T., Ishitoya, S., Terachi, T., Tachibana, M., Matsushiro, H., Habuchi, T., Kakehi, Y., and Ogawa, O., 2002, Genetic polymorphisms of the interleukin-4 receptor alpha gene are associated with an increasing risk and a poor prognosis of sporadic renal cell carcinoma in a Japanese population. Clin Cancer Res, 8:2620–2625.
De Vita, F., Orditura, M., Auriemma, A., Infusino, S., Roscigno, A., and Catalano, G., 1998, Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep, 5:649–652.
De Vita, F., Romano, C., Orditura, M., Galizia, G., Martinelli, E., Lieto, E., and Catalano, G., 2001, Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res, 21:45–52.
DeMichele, A., Martin, A.M., Mick, R., Gor, P., Wray, L., Klein-Cabral, M., Athanasiadis, G., Colligan, T., Stadtmauer, E., and Weber, B., 2003, Interleukin-6-174G—>C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res, 63:8051–8056.
Drachenberg, D.E., Elgamal, A.A., Rowbotham, R., Peterson, M., and Murphy, G.P., 1999, Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate, 41:127–133.
Gado, K., Domjan, G., Hegyesi, H., and Falus, A., 2000, Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma. Cell BiolInt, 24:195–209.
Plante, M., Rubin, S.C., Wong, G.Y., Federici, M.G., Finstad, C.L., and Gastl, G.A., 1994, Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer, 73:1882–1888.
Thiounn, N., Pages, F., Flam, T., Tartour, E., Mosseri, V., Zerbib, M., Beuzeboc, P., Deneux, L., Fridman, W.H., and Debre, B., 1997, IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol Lett, 58:121–124.
Yokoe, T., Iino, Y., and Morishita, Y., 2000,Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report. Breast Cancer, 7:187–190.
Kozlowski, L., Zakrzewska, I., Tokajuk, P., and Wojtukiewicz, M.Z., 2003, Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst, 48:82–84.
Lech-Maranda, E., Baseggio, L., Bienvenu, J., Charlot, C., Berger, F., Rigal, D., Warzocha, K., Coiffier, B., and Salles, G., 2003, The interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma, Blood.
Hattori, E., Okumoto, K., Adachi, T., Takeda, T., Ito, J., Sugahara, K., Watanabe, H., Saito, K., Saito, T., Togashi, H., and Kawata, S., 2003, Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma. Hepatol Res, 27:309–314.
Salgami, E.V., Efstathiou, S.P., Vlachakis, V., Sekara, E. V., Syrigos, K.N., and Roussou, P.P., 2002, High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma. Haematologia (Budap), 32:377–387.
Aydin, F., Yilmaz, M., Ozdemir, F., Kavgaci, H., Yavuz, M.N., and Yavuz, A.A., 2002, Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma. Am J Clin Oncol, 25:570–572.
Martinez-Escribano, J.A., Moya-Quiles, M.R., Muro, M., Montes-Ares, O., Hernandez-Caselles, T., Frias, J.F., and Alvarez-Lopez, M.R., 2002, Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res, 12:465–469.
Chandler, S.W., Rassekh, C.H., Rodman, S.M., and Ducatman, B.S., 2002, Immunohistochemical localization of interleukin-10 in human oral and pharyngeal carcinomas. Laryngoscope, 112:808–815.
Galizia, G., Lieto, E., De Vita, F., Romano, C., Orditura, M., Castellano, P., Imperatore, V., Infusino, S., Catalano, G., and Pignatelli, C., 2002, Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interferon Cytokine Res, 22:473–482.
Galizia, G., Orditura, M., Romano, C., Lieto, E., Castellano, P., Pelosio, L., Imperatore, V., Catalano, G., Pignatelli, C., and De Vita, F., 2002, Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol, 102:169–178.
Vassilakopoulos, T.P., Nadali, G., Angelopoulou, M.K., Siakantaris, M.P., Dimopoulou, M.N., Kontopidou, F.N., Rassidakis, G.Z., Doussis-Anagnostopoulou, I.A., Hatzioannou, M., Vaiopoulos, G., Kittas, C., Sarris, A.H., Pizzolo, G., and Pangalis, G.A., 2001, Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica, 86:274–281.
Hatanaka, H., Abe, Y., Kamiya, T., Morino, F., Nagata, J., Tokunaga, T., Oshika, Y., Suemizu, H., Kijima, H., Tsuchida, T., Yamazaki, H., Inoue, H., Nakamura, M., and Ueyama, Y., 2000, Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol, 11:815–819.
De Vita, F., Orditura, M., Galizia, G., Romano, C., Lieto, E., Iodice, P., Tuccillo, C., and Catalano, G., 2000, Serum interleukin-10 is an independent prognostic factor in advanced solid tumors. Oncol Rep, 7:357–361.
De Vita, F., Orditura, M., Galizia, G., Romano, C., Roscigno, A., Lieto, E., and Catalano, G., 2000, Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest, 117:365–373.
Sarris, A.H., Kliche, K.O., Pethambaram, P., Preti, A., Tucker, S., Jackow, C., Messina, O., Pugh, W., Hagemeister, F.B., McLaughlin, P., Rodriguez, M.A., Romaguera, J., Fritsche, H., Witzig, T., Duvic, M., Andreeff, M., and Cabanillas, F., 1999, Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol, 10:433–440.
Cortes, J., and Kurzrock, R., 1997, Interleukin-10 in non-Hodgkin's lymphoma. Leuk.Lymphoma, 26:251–259.
Blay, J.Y., Burdin, N., Rousset, F., Lenoir, G., Biron, P., Philip, T., Banchereau, J., and Favrot, M.C., 1993, Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood, 82:2169–2174.
Soria, J.C., Moon, C., Kemp, B.L., Liu, D.D., Feng, L., Tang, X., Chang, Y.S., Mao, L., and Khuri, F.R., 2003, Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res, 9:1785–1791.
Stassi, G., Todaro, M., Zerilli, M., Ricci-Vitiani, L., Di Liberto, D., Patti, M., Florena, A., Di Gaudio, F., Di Gesu, G., and De Maria, R., 2003, Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res, 63:6784–6790.
Sredni, B., Weil, M., Khomenok, G., Lebenthal, I., Teitz, S., Mardor, Y., Ram, Z., Orenstein, A., Kershenovich, A., Michowiz, S., Cohen, Y.I., Rappaport, Z.H., Freidkin, I., Albeck, M., Longo, D.L., and Kalechman, Y., 2004, Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res, 64:1843–1852.
Sredni, B., Albeck, M., Tichler, T., Shani, A., Shapira, J., Bruderman, I., Catane, R., Kaufman, B., and Kalechman, Y., 1995, Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide. J Clin Oncol, 13:2342–2353.
Mizutani, Y., Bonavida, B., Koishihara, Y., Akamatsu, K., Ohsugi, Y., and Yoshida, O., 1995, Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res, 55:590–596.
Borsellino, N., Belldegrun, A., and Bonavida, B., 1995, Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res, 55:4633–4639.
Honemann, D., Chatterjee, M., Savino, R., Bommert, K., Burger, R., Gramatzki, M., Dorken, B., and Bargou, R.C., 2001, The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells. Int J Cancer, 93:674–680.
Borsellino, N., Bonavida, B., Ciliberto, G., Toniatti, C., Travali, S., and D'Alessandro, N., 1999, Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer, 85:134–144.
Cavallaro, U. and Christofori, G., 2004, Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer, 4:118–132.
Persad, S. and Dedhar, S., 2003, The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metastasis Rev, 22:375–384.
Felding-Habermann, B., 2003, Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis, 20:203–213.
Lozano, E., Betson, M., and Braga, V.M., 2003, Tumor progression: Small GTPases and loss of cell-cell adhesion. Bioessays, 25:452–463.
Pupa, S.M., Menard, S., Forti, S., and Tagliabue, E., 2002, New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol, 192:259–267.
Hirohashi, S. and Kanai, Y., 2003, Cell adhesion system and human cancer morphogenesis. Cancer Sci., 94:575–581.
Christofori, G., 2003, Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression. EMBO J, 22:2318–2323.
Hecker, T.P. and Gladson, C.L., 2003, Focal adhesion kinase in cancer. Front Biosci, 8:s705–s714.
Conacci-Sorrell, M., Zhurinsky, J., and Ben Ze'ev, A., 2002, The cadherin-catenin adhesion system in signaling and cancer. J Clin Ivest, 109:987–991.
Stracke, M.L., Murata, J., Aznavoorian, S., and Liotta, L.A., 1994, The role of the extracellular matrix in tumor cell metastasis. In Vivo, 8:49–58.
Mason, M.D., Davies, G., and Jiang, W.G., 2002, Cell adhesion molecules and adhesion abnormalities in prostate cancer. Crit Rev Oncol Hematol, 41:11–28.
Cavallaro, U. and Christofori, G., 2001, Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim Biophys Acta, 1552:39–45.
Maeda, K., Kang, S.M., Sawada, T., Nishiguchi, Y., Yashiro, M., Ogawa, Y., Ohira, M., Ishikawa, T., and Hirakawa-YS, C.K., 2002, Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer. Oncol Rep, 9:511–514.
Hoffmann, R., Franzke, A., Buer, J., Sel, S., Oevermann, K., Duensing, A., Probst, M., Duensing, S., Kirchner, H., Ganser, A., and Atzpodien, J., 1999, Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J, Cancer, 79:1742–1745.
Tacyildiz, N., Yavuz, G., Gozdasoglu, S., Unal, E., Ertem, U., Duru, F., Ikinciogullari, A., Babacan, E., Ensari, A., and Okcuoglu-Cavdar, A., 1999, Serum levels and differential expression of intercellular adhesion molecule-1 in childhood leukemia and malignant lymphoma: prognostic importance and relationship with survival. Pediatr Hematol Oncol, 16:149–158.
Zhang, G.J. and Adachi, I., 1999, Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis. Int J Oncol, 14:71–77.
Dosquet, C., Coudert, M.C., Lepage, E., Cabane, J., and Richard, F., 1997, Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res, 3:2451–2458.
Terol, M.J., Lopez-Guillermo, A., Bosch, F., Villamor, N., Cid, M.C., Rozman, C., Campo, E., and Montserrat, E., 1998, Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance. J Clin Oncol, 16:35–40.
Shimizu, Y., Minemura, M., Tsukishiro, T., Kashii, Y., Miyamoto, M., Nishimori, H., Higuchi, K., and Watanabe, A., 1995, Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis. Hepatology, 22:525–531.
Ogawa, Y., Hirakawa, K., Nakata, B., Fujihara, T., Sawada, T., Kato, Y., Yoshikawa, K., and Sowa, M., 1998, Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin Cancer Res, 4:31–36.
Archimbaud, E., Thomas, X., Campos, L., Magaud, J.P., Dore, J.F., and Fiere, D., 1992, Expression of surface adhesion molecules CD54 (ICAM-1) and CD58 (LFA-3) in adult acute leukemia: relationship with initial characteristics and prognosis. Leukemia, 6:265–271.
Gonzalez-Moles, M.A., Bravo, M., Ruiz-Avila, I., Esteban, F., Rodriguez-Archilla, A., Gonzalez-Moles, S., and Arias, B., 2003, Adhesion molecule CD44 as a prognostic factor in tongue cancer. AntiCancer Res, 23:5197–5202.
Vis, A.N., Noordzij, M.A., Fitoz, K., Wildhagen, M.F., Schroder, F.H., and van der Kwast, T.H., 2000, Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol, 164:2156–2161.
Horst, E., Meijer, C.J., Radaszkiewicz, T., Ossekoppele, G.J., Van Krieken, J.H., and Pals, S.T., 1990, Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia, 4:595–599.
Hage, R., Elbers, H.R., Brutel, d.l.R., and van den Bosch, J.M., 1998, Neural cell adhesion molecule expression: prognosis in 889 patients with resected non-small cell lung cancer. Chest, 114:1316–1320.
Poley, S., Stieber, P., Nussler, V., Pahl, H., and Fateh-Moghadam, A., 1997, Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myeloma. AntiCancer Res, 17:3021–3024.
Pujol, J.L., Simony, J., Demoly, P., Charpentier, R., Laurent, J.C., Daures, J.P., Lehmann, M., Guyot, V., Godard, P., and Michel, F.B., 1993, Neural cell adhesion molecule and prognosis of surgically resected lung cancer. Am Rev Respir Dis, 148:1071–1075.
Kibbelaar, R.E., Moolenaar, K.E., Michalides, R.J., Van Bodegom, P.C., Vanderschueren, R.G., Wagenaar, S.S., Dingemans, K.P., Bitter-Suermann, D., Dalesio, O., and Van Zandwijk, N., 1991, Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma. Eur J Cancer, 27:431–435.
Bremnes, R.M., Veve, R., Hirsch, F.R., and Franklin, W.A., 2002, The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer, 36:115–124.
Kuniyasu, H., Ellis, L.M., Evans, D.B., Abbruzzese, J.L., Fenoglio, C.J., Bucana, C.D., Cleary, K.R., Tahara, E., and Fidler, I.J., 1999, Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res, 5:25–33.
Stefansson, I.M., Salvesen, H.B., and Akslen, L.A., 2004, Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol, 22:1242–1252.
Oshita, F., Kameda, Y., Ikehara, M., Tanaka, G., Yamada, K., Nomura, I., Noda, K., Shotsu, A., Fujita, A., Arai, H., Ito, H., Nakayama, H., and Mitsuda, A., 2002, Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer. AntiCancer Res, 22:1065–1070.
Vihinen, P., Nikkola, J., Vlaykova, T., Hahka-Kemppinen, M., Talve, L., Heino, J., and Pyrhonen, S., 2000, Prognostic value of beta1 integrin expression in metastatic melanoma. Melanoma Res, 10:243–251.
Ohira, T., Akutagawa, S., Usuda, J., Nakamura, T., Hirano, T., Tsuboi, M., Nishio, K., Taguchi, F., Ikeda, N., Nakamura, H., Konaka, C., Saijo, N., and Kato, H., 2002, Up-regulated gene expression of angiogenesis factors in post-chemotherapeutic lung cancer tissues determined by cDNA macroarray. Oncol Rep, 9:723–728.
Turner, J.R., Torres, C.M., Wang, H.H., Shahsafaei, A., Richards, W.G., Sugarbaker, D., and Odze, R.D., 2000, Preoperative chemoradiotherapy alters the expression and prognostic significance of adhesion molecules in Barrett's-associated adenocarcinoma. Hum Pathol, 31:347–353.
Kraus, A.C., Ferber, I., Bachmann, S.O., Specht, H., Wimmel, A., Gross, M.W., Schlegel, J., Suske, G., and Schuermann, M., 2002, In vitro chemo-and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene, 21:8683–8695.
Rintoul, R.C. and Sethi, T., 2002, Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin.Sci (Lond), 102:417–424.
Liang, Y., Meleady, P., Cleary, I., McDonnell, S., Connolly, L., and Clynes, M., 2001, Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. Eur J Cancer, 37:1041–1052.
Sherman-Baust, C.A., Weeraratna, A.T., Rangel, L.B., Pizer, E.S., Cho, K.R., Schwartz, D.R., Shock, T., and Morin, P.J., 2003, Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell, 3:377–386.
Miyamoto, H., Murakami, T., Tsuchida, K., Sugino, H., Miyake, H., and Tashiro, S., 2004, Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas, 28:38–44.
Cordes, N., Blaese, M.A., Plasswilm, L., Rodemann, H.P., and Van Beuningen, D., 2003, Fibronectin and laminin increase resistance to ionizing radiation and the cytotoxic drug Ukrain in human tumour and normal cells in vitro. Int J Radiat Biol, 79:709–720.
Vincent, T., Molina, L., Espert, L., and Mechti, N., 2003, Hyaluronan, a major non-protein glycosaminoglycan component of the extracellular matrix in human bone marrow, mediates dexamethasone resistance in multiple myeloma. Br J, Haematol, 121:259–269.
de la Fuente, M.T., Casanova, B., Moyano, J. V., Garcia-Gila, M., Sanz, L., Garcia-Marco, J., Silva, A., and Garcia-Pardo, A., 2002, Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol, 71:495–502.
Damiano, J.S., Hazlehurst, L.A., and Dalton, W.S., 2001, Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia, 15:1232–1239.
Elliott, T. and Sethi, T., 2002, Integrins and extracellular matrix: a novel mechanism of multidrug resistance. Expert Rev Anticancer Ther, 2:449–459.
Shain, K.H., and Dalton, W.S., 2001, Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther, 1:69–78.
Hazlehurst, L.A., and Dalton, W.S., 2001, Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev, 20:43–50.
Shain, K.H., Landowski, T.H., and Dalton, W.S., 2000, The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opin Oncol, 12:557–563.
Hazlehurst, L.A., Landowski, T.H., and Dalton, W.S., 2003, Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene, 22:7396–7402.
Dalton, W.S., 1999, The tumor microenvironment as a determinant of drug response and resistance. Drug Resist Updat, 2:285–288.
Nefedova, Y., Landowski, T.H., and Dalton, W.S., 2003, Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia, 17:1175–1182.
Morin, P.J., 2003, Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat, 6:169–172.
Green, S.K., Francia, G., Isidoro, C., and Kerbek, R.S., 2004, Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther, 3:149–159.
Gray, L.H., Conger, A.D., Ebert, M., Hornsey, S., and Scott, O.C., 1953, The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J, Radiol, 26:638–648.
Crabtree, H.G. and Cramer, W., 1933, The action of radium on cancer cells I. II. Some factors determining the susceptibility of cancer cells to radium. Proc R Soc Ser B, 113:238–250.
Harris, A. L., 2002, Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer, 2:38–47.
Hockel, M., and Vaupel, P., 2001, Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst, 93:266–276.
Vaupel, P., Thews, O., and Hoeckel, M., 2001, Treatment resistance of solid tumors: role of hypoxia and anemia. Med.Oncol, 18:243–259.
Evans, S.M., Judy, K.D., Dunphy, I., Jenkins, W.T., Nelson, P.T., Collins, R., Wileyto, E.P., Jenkins, K., Hahn, S.M., Stevens, C.W., Judkins, A.R., Phillips, P., Geoerger, B., and Koch, C.J., 2004, Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res, 64:1886–1892.
Choi, N., Baumann, M., Flentjie, M., Kellokumpu-Lehtinen, P., Senan, S., Zamboglou, N., and Kosmidis, P., 2001, Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer, 31:43–56.
Saunders, M.I., 1994, Predictive testing of radiosensitivity in non-small cell carcinoma of the lung. Lung Cancer, 10Suppl 1:S83–S90.
Swinson, D.E., Jones, J.L., Richardson, D., Cox, G., Edwards, J.G., and O'Byrne, K.J., 2002, Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer, 37:235–240.
Cruickshank, G.S. and Rampling, R., 1994, Does tumour related oedema contribute to the hypoxic fraction of human brain tumours? Acta Neurochir.Suppl (Wien.), 60:378–380.
Raza, S.M., Lang, F.F., Aggarwal, B.B., Fuller, G.N., Wildrick, D.M., and Sawaya, R., 2002, Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery, 51:2–12.
Spence, A.M., Muzi, M., and Krohn, K.A., 2002, Molecular imaging of regional brain tumor biology. J Cell Biochem.Suppl, 39:25–35.
Brown, J.M., 1999, The hypoxic cell: a target for selective cancer therapy—eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res, 59:5863–5870.
Pugh, C.W., and Ratcliffe, P.J., 2003, Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med, 9:677–684.
Pugh, C.W. and Ratcliffe, P.J., 2003, The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol, 13:83–89.
Semenza, G.L., Agani, F., Feldser, D., Iyer, N., Kotch, L., Laughner, E., and Yu, A. 2000. Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv Exp Med Biol, 475:123–130.
Semenza, G.L., 2000, HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol, 88:1474–1480.
Maxwell, P. H., Pugh, C.W., and Ratcliffe, P.J., 2001, Activation of the HIF pathway in cancer. Curr Opin Genet Dev, 11:293–299.
Royds, J.A., Dower, S.K., Qwarnstrom, E.E., and Lewis, C.E., 1998, Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Pathol, 51:55–61.
Kao, K.S., Xanthoudakis, S., Curran, T., and O'Dwyer, P.J., 1994, Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. Mol Cell Biol, 14:5997–6003.
Minet, E., Michel, G., Mottet, D., Piret, J.P., Barbieux, A., Raes, M., and Michiels, C., 2001, c-JUN gene induction and AP-1 activity is regulated by a JNK-dependent pathway in hypoxic HepG2 cells. Exp Cell Res, 265:114–124.
Flaherty, D.M., Monick, M.M., and Hunninghake, G.W., 2001, AP endonucleases and the many functions of Ref-1. Am J Respir Cell Mol Biol, 25:664–667.
Hall, J.L., Wang, X., Van, A., Zhao, Y., and Gibbons, G.H., 2001, Overexpression of Ref-1 inhibits hypoxia and tumor necrosis factor-induced endothelial cell apoptosis through nuclear factor-kappab-independent and-dependent pathways. Circ Res, 88:1247–1253.
Wang, N. and Stemerman, M.B., 2001, Ref-1 and transcriptional control of endothelial apoptosis. Circ Res, 88:1223–1225.
Kelley, M.R., Cheng, L., Foster, R., Tritt, R., Jiang, J., Broshears, J., and Koch, M., 2001, Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin Cancer Res, 7:824–830.
Wang, G., Reisdorph, R., Clark, Jr., R.E., Miskimins, R., Lindahl, R., and Miskimins, W.K., 2003, Cyclin dependent kinase inhibitor p27(Kip1) is upregulated by hypoxia via an ARNT dependent pathway. J Cell Biochem, 90:548–560.
Goda, N., Ryan, H.E., Khadivi, B., McNulty, W., Rickert, R.C., and Johnson, R.S., 2003, Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol, 23:359–369.
Fujii, T., Otsuki, T., Moriya, T., Sakaguchi, H., Kurebayashi, J., Yata, K., Uno, M., Kobayashi, T., Kimura, T., Jo, Y., Kinugawa, K., Furukawa, Y., Morioka, M., Ueki, A., and Tanaka, H., 2002, Effect of hypoxia on human seminoma cells. Int J Oncol, 20:955–962.
Krtolica, A., Krucher, N.A., and Ludlow, J.W., 1999, Molecular analysis of selected cell cycle regulatory proteins during aerobic and hypoxic maintenance of human ovarian carcinoma cells. Br J, Cancer, 80:1875–1883.
Krtolica, A., Krucher, N.A., and Ludlow, J.W., 1998, Hypoxia-induced pRB hypophosphorylation results from downregulation of CDK and upregulation of PP1 activities. Oncogene, 17:2295–2304.
Carmeliet, P., Dor, Y., Herbert, J.M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C.J., Ratcliffe, P., Moons, L., Jain, R.K., Collen, D., Keshert, E., and Keshet, E., 1998, Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature, 394:485–490.
Sowter, H.M., Ratcliffe, P.J., Watson, P., Greenberg, A.H., and Harris, A.L., 2001, HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res, 61:6669–6673.
Bruick, R.K., 2000, Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci, USA, 97:9082–9087.
Sowter, H.M., Ferguson, M., Pym, C., Watson, P., Fox, S.B., Han, C., and Harris, A.L., 2003, Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. J Pathol, 201:573–580.
Kothari, S., Cizeau, J., McMillan-Ward, E., Israels, S.J., Bailes, M., Ens, K., Kirshenbaum, L.A., and Gibson, S.B., 2003, BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene, 22:4734–4744.
Regula, K.M., Ens, K., and Kirshenbaum, L.A., 2002, Inducible expression of BNIP3 provokes mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes. Circ Res, 91:226–231.
Guo, K., Searfoss, G., Krolikowski, D., Pagnoni, M., Franks, C., Clark, K., Yu, K.T., Jaye, M., and Ivashchenko, Y., 2001, Hypoxia induces the expression of the pro-apoptotic gene BNIP3. Cell Death Differ, 8:367–376.
Park, S.Y., Billiar, T.R., and Seol, D.W., 2002, Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biochem Biophys Res Commun, 291:150–153.
Erler, J.T., Cawthorne, C.J., Williams, K.J., Koritzinsky, M., Wouters, B.G., Wilson, C., Miller, C., Demonacos, C., Stratford, I.J., and Dive, C., 2004, Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and-independent mechanisms and contributes to drug resistance. Mol Cell Biol, 24:2875–2889.
Wartenberg, M., Ling, F.C., Muschen, M., Klein, F., Acker, H., Gassmann, M., Petrat, K., Putz, V., Hescheler, J., and Sauer, H., 2003, Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J, 17:503–505.
Comerford, K.M., Wallace, T.J., Karhausen, J., Louis, N.A., Montalto, M.C., and Colgan, S.P., 2002, Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res, 62:3387–3394.
Liang, B.C., 1996, Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol, 29:149–155.
Sakata, K., Kwok, T.T., Murphy, B.J., Laderoute, K.R., Gordon, G.R., and Sutherland, R.M., 1991, Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br J, Cancer, 64:809–814.
Krishnamurthy, P., Ross, D.D., Nakanishi, T., Bailey-Dell, K., Zhou, S., Mercer, K.E., Sarkadi, B., Sorrentino, B.P., and Schuetz, J.D., 2004, The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem, 279:24218–24225.
Brinkmann, U., 2002, Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P glycoprotein expression and activity in vivo. Novartis Found Symp, 243:207–210.
Doyle, L.A. and Ross, D.D., 2003, Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene, 22:7340–7358.
Germann, U.A., 1996, P-glycoprotein—a mediator of multidrug resistance in tumour cells. Eur J Cancer, 32A:927–944.
Gottesman, M.M., Pastan, I., and Ambudkar, S.V., 1996, P-glycoprotein and multidrug resistance. Curr Opin Genet Dev, 6:610–617.
Mazure, N.M., Brahimi-Horn, M.C., and Pouyssegur, J., 2003, Protein kinases and the hypoxia-inducible factor-1, two switches in angiogenesis. Curr Pharm Des, 9:531–541.
Choi, K.S., Bae, M.K., Jeong, J.W., Moon, H.E., and Kim, K.W., 2003, Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol, 36:120–127.
Berra, E., Pages, G., and Pouyssegur, J., 2000, MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev, 19:139–145.
Levy, A.P., Levy, N.S., Iliopoulos, O., Jiang, C., Kaplin, Jr., W.G., and Goldberg, M.A., 1997, Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kidney Int, 51:575–578.
Ishibashi, H., Shiratuchi, T., Nakagawa, K., Onimaru, M., Sugiura, T., Sueishi, K., and Shirasuna, K., 2001, Hypoxia-induced angiogenesis of cultured human salivary gland carcinoma cells enhances vascular endothelial growth factor production and basic fibroblast growth factor release. Oral Oncol, 37:77–83.
Baek, J.H., Jang, J.E., Kang, C.M., Chung, H.Y., Kim, N.D., and Kim, K.W., 2000, Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene, 19:4621–4631.
Brogi, E., Schatteman, G., Wu, T., Kim, E.A., Varticovski, L., Keyt, B., and Isner, J.M., 1996, Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Ivest, 97:469–476.
Suzuki, H., Seto, K., Shinoda, Y., Mori, M., Ishimura, Y., Suematsu, M., and Ishii, H, 1999, Paracrine upregulation of VEGF receptor mRNA in endothelial cells by hypoxia-exposed hep G2 cells. Am.J Physiol, 276:G92–G97.
Le, Y.J. and Corry, P.M., 1999, Hypoxia-induced bFGF gene expression is mediated through the JNK signal transduction pathway. Mol Cell Biochem, 202:1–8.
Scarpino, S., Cancellario, d.F., Di Napoli, A., Pasquini, A., Marzullo, A., and Ruco, L.P., 2004, Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol, 202:352–358.
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., and Comoglio, P.M., 2003, Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 3:347–361.
Bae, S.K., Bae, M.H., Ahn, M.Y., Son, M.J., Lee, Y.M., Bae, M.K., Lee, O.H., Park, B.C., and Kim, K.W., 1999, Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. Cancer Res, 59:5989–5994.
Kim, K.W., Bae, S.K., Lee, O.H., Bae, M.H., Lee, M.J., and Park, B.C., 1998, Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res, 58:348–351.
Sugawara, J., Tazuke, S.I., Suen, L.F., Powell, D.R., Kaper, F., Giaccia, A.J., and Giudice, L.C., 2000, Regulation of insulin-like growth factor-binding protein 1 by hypoxia and 3′,5′-cyclic adenosine monophosphate is additive in HepG2 cells. J Clin Endocrinol Metab, 85:3821–3827.
Sugawara, J., Suh, D.S., Faessen, G.H., Suen, L.F., Shibata, T., Kaper, F., Giaccia, A.J., and Giudice, L.C., 2000, Regulation of insulin-like growth factor-binding protein-1 by nitric oxide under hypoxic conditions. J Clin Endocrinol Metab, 85:2714–2721.
Patel, B., Khaliq, A., Jarvis-Evans, J., McLeod, D., Mackness, M., and Boulton, M., 1994, Oxygen regulation of TGF-beta 1 mRNA in human hepatoma (Hep G2) cells. Biochem Mol BiolInt, 34:639–644.
Gunaratnam, L., Morley, M., Franovic, A., de Paulsen, N., Mekhail, K., Parolin, D.A., Nakamura, E., Lorimer, I.A., and Lee, S., 2003, Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem, 278:44966–44974.
Cooper, A.L. and Beasley, D., 1999, Hypoxia stimulates proliferation and interleukin-1alpha production in human vascular smooth muscle cells. Am J Physiol, 277:H1326–H1337.
Hagberg, H., Gilland, E., Bona, E., Hanson, L.A., Hahin-Zoric, M., Blennow, M., Holst, M., McRae, A., and Soder, O., 1996, Enhanced expression of interleukin (IL)-1 and IL-6 messenger RNA and bioactive protein after hypoxia-ischemia in neonatal rats. Pediatr Res, 40:603–609.
Liu, M.T., Huang, H.M., Jeng, K.C., Ou, S.C., and Kuo, J.S., 2000, Induction of cytokine genes and IL-1alpha by chemical hypoxia in PC12 cells. Life Sci, 67:2147–2157.
Maeda, Y., Matsumoto, M., Hori, O., Kuwabara, K., Ogawa, S., Yan, S.D., Ohtsuki, T., Kinoshita, T., Kamada, T., and Stern, D.M., 1994, Hypoxia/reoxygenation-mediated induction of astrocyte interleukin 6: a paracrine mechanism potentially enhancing neuron survival. J Exp Med, 180:2297–2308.
Matsui, H., Ihara, Y., Fujio, Y., Kunisada, K., Akira, S., Kishimoto, T., and Yamauchi-Takihara, K., 1999, Induction of interleukin (IL)-6 by hypoxia is mediated by nuclear factor (NF)-kappa B and NF-IL6 in cardiac myocytes. Cardiovasc Res, 42:104–112.
Muraoka, K., Shimizu, K., Sun, X., Zhang, Y.K., Tani, T., Hashimoto, T., Yagi, M., Miyazaki, I., and Yamamoto, K., 1997, Hypoxia, but not reoxygenation, induces interleukin 6 gene expression through NF-kappa B activation. Transplantation, 63:466–470.
Grutkoski, P.S., Graeber, C.T., D'Amico, R., Keeping, H., and Simms, H.H., 1999, Regulation of IL-8RA (CXCR1) expression in polymorphonuclear leukocytes by hypoxia/reoxygenation. J Leukoc Biol, 65:171–178.
Shi, Q., Abbruzzese, J.L., Huang, S., Fidler, I.J., Xiong, Q., and Xie, K., 1999, Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res, 5:3711–3721.
Xu, L., Xie, K., Mukaida, N., Matsushima, K., and Fidler, I.J., 1999, Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res, 59:5822–5829.
Yoshino, O., Osuga, Y., Koga, K., Hirota, Y., Yano, T., Tsutsumi, O., Fujimoto, A., Kugu, K., Momoeda, M., Fujiwara, T., and Taketani, Y., 2003, Upregulation of interleukin-8 by hypoxia in human ovaries. Am J Reprod Immunol, 50:286–290.
Reynolds, T.Y., Rockwell, S., and Glazer, P.M., 1996, Genetic instability induced by the tumor microenvironment. Cancer Res, 56:5754–5757.
Mihaylova, V.T., Bindra, R.S., Yuan, J., Campisi, D., Narayanan, L., Jensen, R., Giordano, F., Johnson, R.S., Rockwell, S., and Glazer, P.M., 2003, Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol Cell Biol, 23:3265–3273.
Kim, C.Y., Tsai, M.H., Osmanian, C., Graeber, T.G., Lee, J.E., Giffard, R.G., DiPaolo, J.A., Peehl, D.M., and Giaccia, A.J., 1997, Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res, 57:4200–4204.
Graeber, T.G., Osmanian, C., Jacks, T., Housman, D.E., Koch, C.J., Lowe, S.W., and Giaccia, A.J., 1996, Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 379:88–91.
von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L.O., Clark, P., Talbot, D., Rey, A., Butler, T.W., Hirsh, V., Olver, I., Bergman, B., Ayoub, J., Richardson, G., Dunlop, D., Arcenas, A., Vescio, R., Viallet, J., and Treat, J., 2000, Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol, 18:1351–1359.
Peters, K.B., and Brown, J.M., 2002, Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res, 62:5248–5253.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer
About this chapter
Cite this chapter
Wei, Y., Au, J.LS. (2005). Role of Tumour Microenvironment in Chemoresistance. In: Meadows, G.G. (eds) Integration/Interaction of Oncologic Growth. Cancer Growth and Progression, vol 15. Springer, Dordrecht. https://doi.org/10.1007/1-4020-3414-8_17
Download citation
DOI: https://doi.org/10.1007/1-4020-3414-8_17
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-3413-8
Online ISBN: 978-1-4020-3414-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)